FIVE-YEAR OUTCOMES WITH NIVOLUMAB IN PATIENTS WITH WILD-TYPE BRAF ADVANCED MELANOMA
The authors report the 5-year outcomes of this multicenter, double-blind, phase III study of nivolumab versus dacarbazine for the first-line treatment of 418 patients with unresectable stage III/IV, wild-type BRAF melanoma. Benefits for overall survival, progression-free survival, and objective response rate with nivolumab were confirmed. The 5-year overall survival rate was 39% with nivolumab. Among […]
FIVE-YEAR OUTCOMES WITH NIVOLUMAB IN PATIENTS WITH WILD-TYPE BRAF ADVANCED MELANOMA Read More »
